49 results about "7-ethyl-10-hydroxycamptothecin" patented technology

The invention discloses an amphiphilic prodrug of 7- ethyl-10-hydroxycamptothecin, which is prepared by connecting hydroxyl at the site 10 and/or 20 site of the 7-ethyl-10- hydroxycamptothecin and a hydrophilic group through a scissionable chemical bond. The amphiphilic prodrug is self-assembled in water to form a micelle or vesicle structure. Therefore, on one hand, the solubility of SN-38 in water is greatly increased, and the stability of SN-38 lactone rings is improved; and on the other hand, the drug loading rate is high and the SN-38 can be quickly released in cells, consequently the defect of low drug loading rate of traditional drugs is overcame. Moreover, with the nano-micelles or the nano-vesicles of the prodrug, EPR (enhanced permeability and retention) effect targeted cancer tissues of tumors can be effectively utilized.

The invention discloses a 7-ethyl-10-hydroxycamptothecine drug precursor, a preparation method and an application thereof. A structure formula of the drug precursor is represented as the formula I or II. The drug precursor is prepared through an esterification reaction between a C-10 hydroxyl group or a C-20 hydroxyl group of 7-ethyl-10-hydroxycamptothecine and a hydrophobic molecule. The drug precursor has excellent anti-tumor activity and can directly release active components in vivo in a hydrolysis manner without catalytic hydrolysis of carboxylesterase, thereby achieving a high bioavailability. The drug precursor not only has excellent solubility in water but also has great solubility in amphipathic surfactants, such as tween-80 and the like, wherein the solubility can reach more than 30 mg/ml, and a high stability is achieved even that the drug precursor is diluted in water. The drug precursor can be prepared just through a one-step esterification method, is high in yield and low in preparation cost, is high in stability and good in safety, satisfies requirements in clinical medication and in large-scale industrial production, and has excellent market prospect and clinical application value.

The invention discloses a 7-ethyl-10-hydroxycamptothecin amphiphilic polymer prodrug comprising a segment of polyethylene glycols and a segment of poly(7-ethyl-10-hydroxycamptothecin); and the poly(7-ethyl-10-hydroxycamptothecin) is formed in the way that hydroxyls at the tenth position or/and twentieth position on 7-ethyl-10-hydroxycamptothecin are connected with a polymer framework through degradable chemical bonds. Polyethylene glycols with different lengths are introduced, so that the prodrug is self-assembled in water to form nano particles, and the solubility of the 7-ethyl-10-hydroxycamptothecin in water is greatly increased. The nanometer size of the polymer prodrug is adjustable so that the 7-ethyl-10-hydroxycamptothecin amphiphilic polymer prodrug can effectively meet the requirement for sizes under different tumor systems and target different intracorporeal organs, and cancers of different organs are possibly treated.

The present invention discloses a four-arm- polyethylene glycol-7-ethyl-10-hydroxy-camptothecin conjugate (formula I), method for preparing the conjugate and method for treating mammal using the conjuagate.

The present invention relates to a process for the preparation of pure irinotecan or salts thereof, and a process for the preparation of intermediate compound 7-ethyl-10-hydroxycamptothecin.

The present invention relates to methods of treatment of neuroblastoma. The present invention includes administering polymeric prodrugs of 7-ethyl-10-hydroxycamptothecin to patients in need thereof.

The invention relates to the technical field of medicine, and relates to a saturated long-chain fatty acid-modified 7-ethyl-10-hydroxycamptothecin (SN-38) compound and a long-circulating liposome thereof. Under substitution reaction conditions and the existence of an acid-binding agent, SN-38 is subjected to saturated long-chain fatty acid chloride, such that a SN-38 monounsaturated fatty acid ester compound is obtained. The compound has a following general formula (I). The long-circulating liposome prepared with the compound provided by the invention has the advantages of improving drug anti-tumor effect, enhancing drug stability, reducing drug toxic and side effects, and the like.

The invention belongs to the technical field of medicine, and relates to a lyophilized powder for injection of a long-circulated thermal sensitive liposome containing 7-ethyl-10-hydroxycamptothecin and a preparation method thereof. The lyophilized powder for injection comprises 1%-30% of 7-ethyl-10-hydroxycamptothecin, 10%-90% of phosphatide, 0%-10% of octadecylamine, 0%-70% of a lyophilizing protective agent, 0%-50% of accessory G, 0.001%-50% of an antioxidant, 0%-30% of cholesterol, 0%-50% of thermal sensitive accessory H, and a balanced amount of a buffer solution. The long-circulated thermal sensitive liposome containing 7-ethyl-10-hydroxycamptothecin has improved water-solubility and stability, and has reduced toxicity.

The invention belongs to the medical technical field, and discloses 7-ethyl-10-hydroxycamptothecine liposome freeze-dried powder injection and a preparation method thereof. The 7-ethyl-10-hydroxycamptothecine liposome freeze-dried powder injection comprises the following components: 1-10g of 7-ethyl-10-hydroxycamptothecine, 30-60g of phospholipids, 10-40g of cholesterol, 2-8g of VE, 100-300g of a freeze drying protectant, 2000-8000ml of an organic solvent, 1000-4000ml of alkaline buffer salt solution and 1000-4000ml of acid buffer salt solution. The preparation method comprises the following steps: dissolving liposoluble components in the organic solvent and water-soluble components in the alkaline buffer salt; transferring the organic solvent, and then adding the alkaline buffer salt for hydration; and carrying freeze drying in vacuum, re-dissolving with the acid buffer salt, incubating, filtering, sterilizing, and carrying out freeze drying again to obtain the 7-ethyl-10-hydroxycamptothecine liposome freeze-dried powder injection for injection. The invention solves the problems of low solubility and fast in-vivo metabolism of the 7-ethyl-10-hydroxycamptothecine, thus lowering toxic reaction, eliminating side reaction, having higher target distribution characteristics, prolonging metabolism time and improving solubility and bioavailability.

The invention provides a method for preparing irinotecan hydrochloride. The method reacts the intermediate 7-ethyl-10-hydroxycamptothecin with 4-piperidinylpiperidine carboxylic acid chloride or its salt in the presence of 4-dimethylaminopyridine or its salt, or its analogue, The final product is obtained through steps such as concentration, washing, and salt formation. The method of the invention avoids the use of malodorous and easily discolored pyridine to participate in the reaction, reduces side reactions, improves the purity and yield of the product, improves the color of the product at the same time, and is easy for large-scale production.

The present invention relates to methods of inhibiting angiogenesis in mammals. The present invention includes administering polymeric prodrugs of 7-ethyl-10-hydroxycamptothecin to the mammals in need thereof. The present invention also relates to methods of treating a disease associated with angiogenesis in mammals by administering polymeric prodrugs of 7-ethyl-10-hydroxycamptothecin to the mammals in need thereof.

The invention relates to an amphiphilic polymer prodrug for reducing responsive 7-ethyl-10-hydroxycamptothecine and a preparation method thereof. The amphiphilic polymer prodrug has the molecular structure as shown in the specification, wherein the polymerization degree n is 5-1000 and m is 1 or 2. According to the prodrug, targeted drug delivery can be realized, and therefore the advantages of anano drug carrier system are kept, and meanwhile, the characteristic that a disulfide bond is specifically degraded in a tumor site can be achieved. Compared with conventional 2,2'-disulfanediyldiacetic acid, 3,3'-dithiodipropionic acid and other connecting arms, the prodrug and the preparation method thereof have the advantage that an anticancer drug in an active compound molecular form can be obtained without further hydrolysis.

The invention relates to the field of pharmacy, in particular to a nano-medicine of a biogenic macrocyclic molecule and a preparation method of the nano-medicine. The nano-medicine of the biogenic macrocyclic molecule comprises 7-ethyl-10-hydroxycamptothecin and a phospholipid nanodisk transporting the 7-ethyl-10-hydroxycamptothecin, and the phospholipid nanodisk comprises a hydrophobic surface facing interior lipid and a hydrophilic surface facing outwards. The nano-medicine has excellent anti-tumor properties, negligible general toxicity and long-term immunotoxicity. The preparation method is simple in operation and mild in reaction conditions, and the nano-medicine can be rapidly prepared and obtained.

The invention relates to a novel 7-ethyl-10-hydroxycamptothecine crystal and a preparation method thereof. According to the novel 7-ethyl-10-hydroxycamptothecine crystal, X-ray powder which is radiated by using Cu-Ka and expressed through a 2 theta angle has characteristic peaks at diffraction angles of 7.1 degrees, 10.26 degrees, 11.36 degrees, 13.22 degrees, 14.14 degrees, 16.12 degrees, 17.86 degrees, 18.74 degrees, 19.5 degrees, 20.18 degrees, 21.98 degrees, 22.74 degrees, 23.64 degrees, 24.6 degrees, 25.28 degrees, 26.52 degrees and 29.84 degrees, and the error range of 2 theta is +/-0.2 degree. The novel 7-ethyl-10-hydroxycamptothecine crystal disclosed by the invention is high in solubility. The preparation method disclosed by the invention is simple, easy to operate and suitable for technical production.

The invention relates to 7-ethyl-10-hydroxycamptothecine crystal forms II and III, and a preparation method and application thereof. The crystal form II uses Cu-K alpha radiation; the X-ray powder diffraction represented by 2theta angle has characteristic peaks when the diffraction angle is 5.64, 10.80, 12.55, 13.48, 17.09, 17.65, 18.21, 18.79, 24.52 and 26.84 degrees; and the error range of 2theta is +/-0.2 degree. The crystal form III uses Cu-K alpha radiation; the X-ray powder diffraction represented by 2theta angle has characteristic peaks when the diffraction angle is 4.58, 9.34, 10.42, 11.12, 12.30, 13.40, 14.40, 16.34, 16.86, 17.20, 17.70, 18.72, 19.32, 21.48, 22.44, 24.90, 25.40, 25.68 and 27.44 degrees; and the error range of 2theta is +/-0.2 degree. The two crystal forms of 7-ethyl-10-hydroxycamptothecine have high solubility and favorable stability.

The method of manufacturing of 7-ethyl-10-hydroxycamptothecin of formula I characterized in that 7-ethyl-1,2,6,7-tetrahydrocampotothecin of formula IV is oxidized with an oxidizing agent selected from the group coprising iodosobenzene, an ester of iodosobenzene, sodium periodate, potassium periodate, potassium peroxodisulfate and ammonium peroxodisulfate, in a solvent formed by a saturated aliphatic monocarboxylic acid containing 1 to 3 carbon atoms, and in the presence of water.